GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077) - Trial NCT01355003

Name: Clinical Trial NCT01355003
Creator: Merck Sharp & Dohme LLC
Keywords: Papillomavirus Infections, clinical trial

Access comprehensive clinical trial information for NCT01355003 through Pure Global AI's free database. This phase not specified trial is sponsored by Merck Sharp & Dohme LLC and is currently Terminated. The study focuses on Papillomavirus Infections. Target enrollment is 1080 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

NCT01355003

Terminated

Trial Details

ClinicalTrials.gov • NCT01355003

View on ClinicalTrials.gov

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol

Study Focus

Disease/Condition

Papillomavirus Infections

Study Type

Observational

Sponsor & Location

Primary Sponsor

Merck Sharp & Dohme LLC

Timeline & Enrollment

Phase

N/A

Start Date

Feb 01, 2008

End Date

Jun 01, 2010

Enrollment

1080 participants

Primary Outcome

Number of participants with adverse events following any dose of vaccine

Summary

This study will collect safety information on the use of GARDASIL™ in the Philippines.

ICD-10 Classifications

Papillomavirus as the cause of diseases classified to other chapters

Papovavirus infection, unspecified site

Papilloedema, unspecified

Viral infection, unspecified

Parvovirus as the cause of diseases classified to other chapters

Data Source

Registry

ClinicalTrials.gov

Trial ID

NCT01355003

Type

Non-Device Trial